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Abbreviations: PLGA, poly(lactic-co-glycolic acid); pNIPAM, poly(N-isopropylacrylamide); EPR, enhanced permeability and
retention; LCST, lower critical solution temperature; PVA, polyvinyl alcohol; AAc, acrylic acid; TEM, transmission electron
microscopy; THP1, human monocytes; DCM, dichloromethane; FMOC, 9-fluorenylmethyloxycarbonyl; HOBt, N-
hydroxybenzotriazole; DIC, N,N’ diisopropylcarbodiimide; HBTU, O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-
phosphate; EDC, 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride; sulfo-NHS, N-hydroxylsulfosuccinimide; MES, 2-
(N-morpholino)ethanesulfonic acid; BMPH, N-[β-maleimidopropionic acid] hydrazide; BSA, bovine serum albumin; PMA, phorbol
12-myristate 13-acetate; LPS, lipopolysaccharide; PBS, phosphate buffered saline; TNF-a, tumor necrosis factor-a; ELISA, enzyme-
linked immunosorbent assay; ABTS, 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid), N-methyl-bis-acrylamide, MBAm
Poly(lactic-co-glycolic acid) (PLGA) is a popular material used to prepare nanoparticles for drug delivery. However, PLGA
nanoparticles lack desirable attributes including active targeting abilities, resistance to aggregation during lyophilization,
and the ability to respond to dynamic environmental stimuli. To overcome these issues, we fabricated a nanoparticle
consisting of a PLGA core encapsulated within a shell of poly(N-isopropylacrylamide). Dynamic light scattering and
transmission electron microscope imaging were used to characterize the nanoparticles, while an MTT assay and ELISA
suggested biocompatibility in THP1 cells. Finally, a collagen type II binding assay showed successful modification of these
nanoparticles with an active targeting moiety.
Introduction
Poly(lactic-co-glycolic acid) (PLGA) is a biocompatible, biodegrad-
able synthetic polymer that is easy to fabricate into size-specific
nanoparticles and has a well-documented ability for sustained
therapeutic release.1-3 Although many investigators and commercial
entities have embraced these desirable attributes to construct PLGA
nanoparticles for use in research and commercial products,1,3-5
PLGA nanoparticles still have significant limitations when it comes
to using them to deliver therapeutics to a specific disease site. One
such limitation is that PLGA nanoparticles, when delivered
intravenously, have no active targeting capabilities and are restricted
to passive targeting via the enhanced permeability and retention
(EPR) effect seen in cancerous and inflamed tissues.6-8 Tissue
accumulation via the EPR effect can provide potential benefits for
cancer drug delivery,6 but it renders drug delivery for other disease
states that lack the EPR effect problematic. Other investigators have
attempted to overcome this challenge by modifying PLGA
nanoparticles for “active” targeting with the addition of monoclonal
antibodies.9 Another challenge is the long-term storage of aqueous
suspensions of PLGA nanoparticle systems, due to hydrolytic
degradation of the polymer and subsequent release of the
encapsulated therapeutic.10,11 To overcome this issue, researchers
have used lyophilization to prepare therapeutic-containing PLGA
nanoparticles for long-term storage.10,11 However, this simple
solution introduces another problem: lyophilization causes the
PLGA nanoparticles to aggregate into clumps that upon rehydra-
tion, readily fall out of solution.10,11 Finally, PLGA nanoparticles
are limited in their responses to environmental stimuli like
temperature or pH. Although environmental sensitivity is not a
requirement for nanoparticle systems, it does provide advantages,
such as the ability to control therapeutic release from nanoparticle
carriers only when they are exposed to environments inherent to
particular disease states.12
*Correspondence to: Alyssa Panitch; Email: apanitch@purdue.edu.
Submitted: 04/03/12; Revised: 08/24/12; Accepted: 10/09/12
http://dx.doi.org/10.4161/biom.22494
REPORT
Biomatter 2:4, 1–7; October/November/December 2012; G 2012 Landes Bioscience
www.landesbioscience.com Biomatter 1
In an effort to overcome the limitations associated with PLGA
nanoparticles, as well as increase their functionality, we developed
a method to encapsulate PLGA nanoparticles within a shell of
poly(N-isopropylacrylamide) (pNIPAM). pNIPAM was chosen
because it is a versatile material with some inherently unique
properties. The pNIPAM shell can be synthesized as a
homopolymer, or as a copolymer with incorporation of a variety
of chemical moieties with defined concentrations that can then be
further modified with active targeting functional groups.13-15
Additionally, pNIPAM can tolerate lyophilization;16 we hypothe-
sized that a pNIPAM shell would protect encapsulated PLGA
nanoparticles from aggregation during lyophilization. Finally,
pNIPAM is a temperature responsive polymer that can undergo a
phase transition at a lower critical solution temperature (LCST)
around 31–32°C.17 At temperatures below its LCST, pNIPAM
nanoparticles are swollen and hydrophilic.13 However, once the
temperature increases above the LCST, pNIPAM nanoparticles
collapse as the polymer becomes hydrophobic.13 Thus, by
encapsulating PLGA nanoparticles in a pNIPAM shell, the
nanoparticles should have the ability to respond to environmental
stimuli, such as temperature. This response could then be used for
loading and/or controlling the release of therapeutics from the
pNIPAM layer.18 In this paper, we characterize this novel PLGA
core + pNIPAM shell nanoparticle system.
Results and Discussion
Physical characterization of the core + shell nanoparticles.
Nanoparticles were formed through a two-step process that
included: the formation of a PLGA core followed by the synthesis
of a pNIPAM shell around these pre-formed PLGA cores (Fig. 1).
Verification of successful encapsulation of the PLGA cores with
the pNIPAM shells was initially achieved using dynamic light
scattering to measure the size of the nanoparticles before and after
the addition of the shell to determine the change in nanoparticle
diameter. The diameter of the core + shell nanoparticles (Table 1)
increased post addition of the pNIPAM shell, suggesting
successful encapsulation. pNIPAM shell thickness ranged from
~100 nm to ~200 nm at 25°C, where an increase in shell
thickness corresponded to an increase in the mole percent of
acrylic acid, and therefore charge density. This phenomenon has
been shown previously in the literature.19
Additional verification of successful encapsulation of the
pNIPAM shell was provided by confirming a phase transition
when the temperature was raised above its LCST. Because
pNIPAM is a temperature sensitive polymer, we expected to see a
difference in nanoparticle size, with the nanoparticle diameter
being smaller at 37°C (above pNIPAM LCST) compared with
25°C (below pNIPAM LCST). All core + shell nanoparticles
showed reduced diameters at 37°C compared with 25°C (Table
1). This trend is most pronounced with shell thicknesses that at
37°C range only from ~10 nm to ~100 nm with an increase in
shell thickness again corresponding to an increase in the mole
percent of acrylic acid incorporated into the pNIPAM.
To assess colloidal stability of our core + shell nanoparticles
above and below the phase transition temperature, we measured
their f-potentials. According to the literature, nanoparticle f-
potentials above 30 mV or below -30 mV are considered stable.20
As shown in Table 1, all nanoparticles, are near -30 mV
indicating that they are stable.
Effects of lyophilization on core + shell nanoparticles.
Lyophilization is an effective way to prevent the release of
Figure 1. Schematic of the fabrication of PLGA core + pNIPAM shell nanoparticles (A and B) and the subsequent chemistry (C) used to append the
collagen type II binding peptide targeting ligand.
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therapeutics loaded into PLGA nanoparticles during long-term
storage.10,11 However, if not performed correctly, lyophilization
can result in aggregation of the PLGA nanoparticles that prevents
resolubilization of the clumped nanoparticles (Fig. 2).10,11 We
used TEM imaging to visually confirm that well-defined spherical
PLGA and PLGA core + pNIPAM shell nanoparticles were
successfully fabricated (Fig. 2). However, as also observed by
others,10,11 TEM imaging showed that lyophilization caused the
PLGA nanoparticles to form aggregates (Fig. 2). This aggregation
resulted in an inability to measure diameter and f-potential of
post-lyophilized PLGA nanoparticles. In contrast, encapsulation
of PLGA nanoparticles with pNIPAM shells prevented aggrega-
tion of the PLGA nanoparticles following lyophilization, further
confirming that the pNIPAM shell fully encapsulated the PLGA
core. Additionally, we found that lyophilization of the core + shell
nanoparticles does not affect their size or f-potential at 25°C or
37°C (Table 1).
Responses of core + shell nanoparticles to dynamic envir-
onmental stimuli. To further assess the response of our core +
shell nanoparticles to temperature-based environmental stimuli,
we used dynamic light scattering to measure the diameter of our
core + shell nanoparticles as they were exposed to a dynamic
range of temperatures from 20°C to 50°C to 20°C. We found
that the core + shell nanoparticles readily respond within this
temperature range with all core + shell nanoparticle types
decreasing in diameter as the temperature was raised above their
LCST (Fig. 3). This response was reversible, as the nanoparticles
returned to their original diameter when the temperature was
lowered back below their LCST. Additionally, the LCST of the
pNIPAM shell was tuned by modifying the amount of acrylic
acid that was incorporated as a co-monomer. As more acrylic
acid was incorporated, the LCST of pNIPAM increased (Fig. 3).
The core + shell nanoparticles with 0 mol% acrylic acid exhibited
an LCST at ~31–32°C, while the 1 mol% acrylic acid had an
LCST at ~33–34°C, and the core + shell nanoparticles with 5
mol% acrylic acid had an LCST at ~35°C (Fig. 3). This trend
has previously been established in the literature.19,21 In the
future, these core + shell nanoparticles could be engineered to
respond to different environmentally based stimuli in addition to
temperature by changing the co-monomer composition of the
pNIPAM.14
Core + shell nanoparticle biocompatibility. The biocompat-
ibility of the core + shell nanoparticles was assessed by evaluating
the toxicity and inflammatory response in an immortalized
human monocyte cell line. This cell line was chosen because, in
Table 1. Characterization of Various Nanoparticle Samples
Sample name Lyophilization? Temperature (°C) Particle diameter (nm)
Zeta potential
(mV)a
Shell thickness
(nm)b
PLGA core No
25 392.3 ± 13.9 -32.1 ± 2.0
NA
37 377.2 ± 20.2 -22.5 ± 3.4
PLGA core + pNIPAM shell
(0 mol% AAc)
No
25 605.3 ± 10.8 -28.3 ± 4.4 106.5 ± 5.4
37 403.8 ± 7.1 -25.0 ± 2.5 13.3 ± 3.6
Yes
25 610.2 ± 14.2 -32.1 ± 0.9 109.0 ± 7.1
37 414.5 ± 7.9 -24.3 ± 1.8 18.6 ± 3.9
PLGA core + pNIPAM shell
(1 mol% AAc)
No
25 659.1 ± 6.7 -28.0 ± 6.0 133.4 ± 3.4
37 428.0 ± 9.5 -22.7 ± 2.7 25.4 ± 4.7
Yes
25 681.7 ± 20.9 -30.8 ± 5.1 144.7 ± 10.4
37 447.0 ± 13.5 -20.5 ± 0.7 34.9 ± 6.8
PLGA core + pNIPAM shell
(5 mol% AAc)
No
25 748.5 ± 17.1 -34.9 ± 2.5 178.1 ± 8.5
37 534.1 ± 14.8 -25.1 ± 3.1 78.4 ± 7.4
Yes
25 818.3 ± 3.9 -34.6 ± 0.2 213.0 ± 2.0
37 575.9 ± 16.6 -25.2 ± 2.1 99.4 ± 8.3
apH of all samples was between 5 and 6. bDetermined by subtracting corresponding core from core + shell sample and dividing by 2.
Figure 2. Transmission electron microscope images of the various
nanoparticles both pre- and post-lyophilization. Scale bars = 250 nm.
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our experience, it shows increased sensitivity to toxicity compared
with other cell lines. Additionally, monocytes have a significant
role in the perpetuation of osteo- and rheumatoid arthritis,22,23 an
inflammatory disease model that will be used to evaluate the
ability of these core + shell nanoparticles to deliver desired
therapeutics in the future. The core + shell nanoparticles were not
toxic at any of the concentrations tested, as we saw no significant
reduction in THP1 cell number (Fig. 4). However, the core +
shell nanoparticles with 5 mol% acrylic acid induced a significant
increase in proliferation of the THP1 cells at concentrations of 2.5
and 5 mg/mL compared with all other treatments (p, 0.05; one-
way ANOVA + Tukey post-hoc test). Next, the ability of the core
+ shell nanoparticles to elicit an inflammatory response was
determined by measuring TNF-a production by THP1 cells
using an ELISA. A significant inflammatory response, character-
ized by an increase in TNF-a production, is not desirable and
would indicate non-biocompatibility. Similar to the PBS control,
the core + shell nanoparticles did not elicit TNF-a production
(Fig. 5; p . 0.05; one-way ANOVA), suggesting these
nanoparticles are biocompatible though further testing will be
conducted in the future to verify this preliminary work. The
positive control, THP1 cells treated with lipopolysacharide, did
induce TNF-a production as expected.
Targeting core + shell nanoparticles. In order to increase the
targeting capabilities of our core + shell nanoparticles beyond the
passive EPR effect,6,7 we modified them with an active targeting
moiety—a peptide that binds collagen type II (Fig. 1).24 This
targeting moiety was chosen because our future work will utilize
these nanoparticles to deliver therapeutics in an arthritic-based
disease model, and collagen type II is readily found in the cartilage
of the joints.25 However, this chemistry could easily be applied to
attach other targeting moieties that contain a free thiol functional
group.
To assess whether incorporation of the collagen type II binding
peptide allowed the core + shell nanoparticles to bind to collagen
type II, we utilized a microplate assay. This assay involved coating
a 96-well plate with collagen type II, incubating it with collagen
type II targeting enabled core + shell nanoparticles, and then
probing for the presence of the biotin labeled collagen type II
peptide. The results from this assay indicate that core + shell
nanoparticles modified with collagen type II binding peptide
bound collagen type II as compared with unmodified core + shell
nanoparticle controls (Fig. 6; p , 0.05, one-way ANOVA +
Tukey post hoc test). Furthermore, the number of collagen type II
binding peptide modified core + shell nanoparticles able to bind
Figure 3. Temperature sweeps of the various nanoparticles. Data are
represented as mean ± standard deviation (n = 3). C, PLGA core only; C
+S #%, PLGA core + pNIPAM shell + mol% acrylic acid; L, Lyophilized.
Figure 4. Toxicity of the core + shell nanoparticles in human monocytes.
φ, p, 0.05 compared with all other treatments (one-way ANOVA +Tukey
post-hoc test). Data are presented as mean ± standard deviation (n = 4).
Figure 5. TNF-a production by human monocytes treated with core +
shell nanoparticles. φ represents statistical significance from all other
data points (p , 0.05, one-way ANOVA + Tukey Post-hoc test). Data
presented as mean ± standard deviation (n = 4).
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to collagen type II was directly related to the concentration of
acrylic acid that was incorporated into the pNIPAM shell.
Materials and Methods
Encapsulating pre-formed PLGA cores within synthesized
pNIPAM shells. Core + shell nanoparticle preparation occurred
in two steps: fabrication of the PLGA cores followed by the
addition of the pNIPAM shell (Fig. 1). First, PLGA cores were
prepared using a single emulsion technique.26 Briefly, 5 g of poly
(dl-lactide/glycolide) 50:50 (PLGA; Polysciences Inc.) were
dissolved in 5 mL of dichloromethane (DCM; Sigma-Aldrich),
added to 20 mL of 5% polyvinyl alcohol (PVA; Alfa Aesar; Avg.
MW = 11,000–31,000), and homogenized for 30 s using a probe
sonicator (Branson Sonifier 450) to generate a single emulsion. The
emulsion was then added to 100 mL of rapidly stirred distilled
water and left overnight to allow for full evaporation of the DCM.
The PLGA nanoparticles were further purified via 4  30 min
centrifugation washes at 10,000 g and 4°C with distilled water. Any
clumps of PLGA nanoparticles that remained after centrifugation
were disrupted using brief sonication. The PLGA cores were then
encapsulated in pNIPAM shells using aqueous free radical
precipitation polymerization under a nitrogen atmosphere.27-29
Briefly, 0.27 g N-isopropylacrylamide (2.385 mmol) (Polysciences
Inc.), 0.021 g N-N’-methylene bisacrylamide (0.136 mmol)
(Fluka), 0.012 g sodium dodecyl sulfate (0.042 mmol) (Sigma
Aldrich), and 0.015 g ammonium persulfate (0.066 mmol) (Sigma
Aldrich) were dissolved in 30 mL of distilled water and purged of
oxygen by nitrogen bubbling. For nanoparticle targeting, either
1.67 mL (0.024 mmol or 1 mol%) or 8.35 mL (0.121 mmol or
5 mol%) of acrylic acid (AAc; Alfa Aesar) were included.
Meanwhile, 20 mL of the PLGA nanoparticle cores were added
to a 250 mL three-neck round bottom flask and equilibrated to
70°C for 20 min under nitrogen with stirring. Then, 10 mL of
the shell solution was added to the 70°C equilibrated PLGA
nanoparticle cores and allowed to polymerize. Additional 5 mL
aliquots of shell solution were added 30, 50, 70 and 90 min
after the initial polymerization. Polymerization continued for
6 h after the final addition of shell solution. Purification was
achieved through dialysis of the PLGA core + pNIPAM shell
nanoparticles against distilled water for 7 d in 15,000 MWCO
dialysis tubing (Spectrum Laboratories, Inc.). Then centrifu-
gation washes were performed to further isolate the core + shell
nanoparticles from any pNIPAM homoparticles that may have
formed. Any clumps of core + shell nanoparticles post
centrifugation purification were dispersed using brief sonication.
Finally, a portion of the samples were lyophilized and then
rehydrated in distilled water.
Transmission electron microscopy (TEM) characterization.
Images were taken of the pre- and post- lyophilized nanoparticle
samples stained with 2% uranyl acetate. The stained nanoparticles
were then placed on a glow-discharged 400 mesh coated with
formvar + carbon film, and then placed in a Philips CM-100
TEM where images were captured on Kodak SO-163 electron
image film.
Nanoparticle sizing and zeta potential. Measurements were
taken with a Malvern Zetasizer Nano ZS90. Pre- and post-
lyophilized nanoparticles were suspended in distilled water and
analyzed for particle size in polystyrene cuvettes at 25°C and 37°C.
Temperature sweeps were performed by varying temperature from
20°C to 50°C to 20°C in 1° increments with measurement of
particle size with each change in degree. Disposable Malvern f-
potential cuvettes were used to measure the f-potential of our
particles at 25°C and 37°C. After making any change in
temperature, nanoparticle samples were allowed to equilibrate for
five minutes before any sizing or zeta measurements were made.
Peptide synthesis and purification. The collagen type II
binding peptide single amino acid sequence consisting of
WYRGRLGC was identified from the literature.24 It was
synthesized at a 0.4 mmol scale on Knorr-amide resin (Synbiosci
Corp.) using standard FMOC (9-fluorenylmethyloxycarbonyl)
chemistry. Two different chemistries were used to couple each
amino acid (Synbiosci Corp). The first coupling reagents consisted
of N-hydroxybenzotriazole (HOBt; Synbiosci) and N,N’ diisopro-
pylcarbodiimide (DIC; Sigma-Aldrich) and the second coupling
reagents were O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-
hexafluoro-phosphate (HBTU; Synbiosci) and lutidine (Sigma-
Aldrich). Following synthesis, the peptide was cleaved from the
resin with 95% trifluoroacetic acid (Sigma-Aldrich), 2.5% water,
1.25% triisopropylsilane (Sigma-Aldrich), and 1.25% ethane-
dithiol (Sigma-Aldrich), precipitated in cold ether, and recovered
by centrifugation. It was then purified with an acetonitrile gradient
on an AKTA Explorer FPLC (GE Healthcare) equipped with a
22/250 C18 reversed phase column (Grace Davidson). Molecular
weight was confirmed by time of flight MALDI mass spectrometry
using a 4800 Plus MALDI TOF/TOF Analyzer (Applied
Biosystems). Theoretical molecular weight of WYRGRLGC was
Figure 6. Collagen Type II binding assay for core + shell nanoparticles.
1% and 5% AAc modified NPs are statistically significant from each other
and the controls as indicated by the different Greek letters (p , 0.05;
one-way ANOVA + Tukey Post-hoc test). Data presented as mean ±
standard deviation (n = 4).
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calculated to be 1,009.1 while the actual molecular weight was
found to be 1,009.58. A biotinylated version of the peptide (biotin-
WYRGRLC) was purchased from Genscript and its theoretical
molecular weight was calculated to be 1,179.42 while its actual
molecular weight was found to be 1,179.8.
Modifying core + shell nanoparticle with targeting moiety.
Nanoparticle targeting was achieved through the addition of a
collagen type II binding peptide to the AAc groups on our core +
shell nanoparticles using a heterobifunctional crosslinker (Fig. 1).
Briefly, 0.4 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDC; Thermo-Scientific) and 1.1 mg of N-
hydroxylsulfosuccinimide (sulfo-NHS; Thermo-Scientific) were
added to 1 mg of core + shell nanoparticles for 15 min in
activation buffer (0.1 M 2-(N-morpholino)ethanesulfonic acid
(MES; Amresco, pH 6.0). Excess EDC and sulfo-NHS was
removed by a centrifuge wash. The heterobifunctional crosslinker,
N-(β-maleimidopropionic acid) hydrazide (BMPH; Thermo-
Scientific) was added to the activated nanoparticles (0.1 mg for 1
mol% AAc nanoparticles or 0.3 mg for 5 mol% AAc nanoparticles)
for 2 h in coupling buffer (0.1 M MES, pH 7.2). Excess BMPH
was removed using gel filtration chromatography through an
ÄKTA Purifier FPLC (GE Healthcare) with Bio-Scale Mini
Bio-Gel columns packed with polyacrylamide beads (Bio-Rad
Laboratories). The collagen type II binding peptide (15%
biotinylated) was added to the nanoparticles for 2 h in coupling
buffer. Excess peptide was removed via gel filtration chromato-
graphy. Confirmation of peptide addition was performed using a
flouraldehyde assay (Pierce), which reacts with free amines, and
a streptavidin color development assay, which confirmed the
presence of the biotinylated peptide on the nanoparticle surface
(data not shown).
Collagen type II binding assay. Modified nanoparticles were
tested for their ability to bind to collagen type II. A 96-well plate
(Greiner) was coated with collagen type II from chicken sternum
(Sigma) in 0.25% acetic acid at a concentration of 0.5 mg/ml
overnight. Following three washes, the plate was blocked with 1%
bovine serum albumin (BSA; SeraCare Life Systems) for 1 h. After
three more washes, the collagen type II binding peptide modified
core + shell nanoparticles and unmodified controls were incubated
in the collagen type II coated plate for 1 h. Following three more
washes, streptavidin (R&D Systems) was diluted 200 in 1%
BSA and incubated for 20 min in the plate. After more washing to
remove unbound streptavidin, a color solution (R&D Systems)
was added for 20 min. Sulfuric acid (Mallinckrodt Chemicals) was
then used to stop the reaction and absorbance was read at 450 nm
with a correction at 540 nm.
Cell culture. Immortalized human monocytes (THP1, ATCC)
were grown in RPMI 1640 with L-glutamine (Mediatech Inc.)
supplemented with 0.05 mM mercaptoethanol (Sigma-Aldrich),
10 mM HEPES (Mediatech Inc.), 1 mM sodium pyruvate
(Mediatech Inc.), 10% fetal bovine serum (Hyclone), and 1%
penicillin/streptomycin (Mediatech Inc.). Cells were used between
passage number 4 and 12 for all assays and maintained at 37°C with
5% CO2.
Nanoparticle biocompatibility. The biocompatibility of the
nanoparticles was assessed bymeasuring toxicity and pro-inflammatory
cytokine expression in THP1 cells. Cells were seeded at a density
of 250,000 cells/mL in 96-well plates (Corning) and treated with
10 ng/mL phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) for
48 h to induce differentiation, which was confirmed by the monocytes
becoming adherent. Following a change of media, cells were treated
with various concentrations of core + shell nanoparticles. Control
samples received PBS (negative control) or 50 ng/mL lipopolysacchar-
ide (LPS, Sigma-Aldrich) (positive control). After 24 h, the media was
collected for cytokine analysis and anMTT-based assay was performed
to determine cell toxicity using the Aqueous One Proliferation Kit
(Promega) according to manufacturer’s instructions. Briefly, 20 mL of
reagent was added directly to 100 mL of cells and media. After two
hours of incubation in the cell culture incubator, the absorbance was
read at 490 nm with a correction at 650 nm.
The ability of the particles to cause an inflammatory response
was determined by running conditioned cell media on a TNF-a
ELISA (PeproTech) according to manufacturer instructions.
Briefly, Nunc MaxiSorp 96-well plates were coated with capture
antibody overnight. After blocking for one hour with 1% bovine
serum albumin (Sera Lifesciences) in PBS, samples and standards
were incubated for two hours with gentle rotation. Following
incubation with a detection antibody and an avidin-horse radish
peroxidase conjugate, the samples were developed with the
addition of 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)
(ABTS) liquid substrate (Sigma-Aldrich) and monitored at
405 nm with a correction at 650 nm.
Statistical Analysis. Data was analyzed for differences using a
single factor ANOVA with a Tukey post-hoc test. A value of p ,
0.05 was used for all analyses. Graphs are depicted as mean ±
standard deviation.
Conclusions
In closing, we successfully encapsulated PLGA core nanoparticles
with a pNIPAM shell. The addition of this pNIPAM shell
conferred many benefits including the ability to protect the PLGA
cores from aggregating during lyophilization, the ability to modify
the nanoparticles with active targeting moieties in a concentra-
tion-dependent manner, and the ability to change size based on
external environmental-based stimuli. These core + shell
nanoparticles are non-toxic and do not elicit an inflammatory
response in THP1 cells suggesting biocompatibility. All of these
abilities will prove important in future in vivo studies focused on
examining the ability of these nanoparticles to deliver therapeutics
in an arthritic-based disease model.
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